Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

Phase 2

Completed

• Conditions: Previous Treated Metastatic Non-small Cell Lung Cancer
• Interventions: Drug: Gefitinib; Drug: Pemetrexed

• Registration Number: NCT01783834
• Lead Sponsor: Gachon University Gil Medical Center

Brief Summary

To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer

Detailed Description

Not available

Study Timeline

• Study Start: 2008-02
• Study First Submitted: 2013-01-30
• Study First Submitted QC: 2013-02-04
• Study First Posted: 2013-02-05
• Primary Completion: 2014-06
• Study Completion: 2014-06
• Status Verified: 2016-02
• Last Update Submitted: 2016-02-10
• Last Update Posted: 2016-02-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 95

Inclusion Criteria

• Cells pathologically diagnosed as histological or radical surgery or radiation therapy is not possible stage IIIB and stage IV non-small-cell lung cancer patients
• second line
• ECOG 0～2
• Patients with normal liver function and renal function

Exclusion Criteria

• Patients with severe acute infection requiring antibiotic therapy
• Patients who have received treatment in other areas of cancer within 5 years
• During pregnancy and lactation patients

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
gefitinib	Gefitinib	gefitinib
pemetrexed	Pemetrexed	pemetrexed

Primary Outcome Measures

Name	Time	Method
Overall response rate	5 years

Secondary Outcome Measures

Name	Time	Method
Progression free survival	5years

Trial Locations

Locations (1)

Gachon university Gil Medical Center; 🇰🇷 Incheon, Korea, Republic of